{"abstract": "After troubles with its anemia treatment Aranesp, which accounts for more than half of profits, Amgen seems to be suffering through a midlife crisis.", "web_url": "https://www.nytimes.com/2007/08/18/business/18values.html", "snippet": "After troubles with its anemia treatment Aranesp, which accounts for more than half of profits, Amgen seems to be suffering through a midlife crisis.", "lead_paragraph": "AMGEN won over investors who viewed it as the first biotechnology company to graduate from adolescence to adulthood. It continued to grow fast, and its new maturity added something that other biotechs lacked: profits.", "print_section": "C", "print_page": "6", "source": "The New York Times", "multimedia": [], "headline": {"main": "Amgen Finds Growing Up Isn\u2019t So Easy", "kicker": "Market Values", "content_kicker": null, "print_headline": "Amgen Finds Growing Up Isn\u2019t So Easy", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Sales", "rank": 2, "major": "N"}, {"name": "organizations", "value": "AMGEN INC", "rank": 3, "major": "N"}], "pub_date": "2007-08-18T04:00:00+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Conrad De Aenlle", "person": [{"firstname": "Conrad", "middlename": null, "lastname": "De Aenlle", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/9df393b7-312e-5340-a3d3-c833ee01fd5f", "word_count": 688, "uri": "nyt://article/9df393b7-312e-5340-a3d3-c833ee01fd5f"}